TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18452048

Group type: EXPERIMENTAL
Intervention: User-friendly Patient Discharge Form and telephone outreach from a nurse
Number of subjects: 100

Group type: COMPARATOR
Intervention: Concurrent controls
Number of subjects: 100

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 100
Study: 15714065

Group type: EXPERIMENTAL
Intervention: Doublecortin (DCX) gene expression
Number of subjects: 34

Group type: COMPARATOR
Intervention: Tyrosine hydroxylase (TH)
Number of subjects: 34
Study: 11836040

Group type: EXPERIMENTAL
Intervention: Soy rich diet
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 187
Study: 11314876

Group type: EXPERIMENTAL
Intervention: Daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) for 2 weeks (total of 16,000 stimuli)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 22
Study: 8646826

Group type: COMPARATOR
Intervention: lamivudine alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: lamivudine plus trimethoprim‐sulfamethoxazole
Number of subjects: 14
Study: 1612820

Group type: EXPERIMENTAL
Intervention: Pretreatment characteristics predicting abstinence at 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Withdrawal discomfort and increased frequency of night awakenings during the first month of abstinence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tendency to 'slip' during Weeks II‐IV
Number of subjects: 0
Study: 6376041

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (C.p.)
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 878

Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 878
Study: 30378768

Group type: EXPERIMENTAL
Intervention: Family-based behavioural weight loss treatment (FBT)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Reducing RED (high-energy-dense and low-nutrient-dense) foods and electronics in the home during FBT
Number of subjects: 181

Group type: COMPARATOR
Intervention: Larger density of public recreation spaces
Number of subjects: 181
Study: 29205515

Group type: EXPERIMENTAL
Intervention: Yoga training (three 1-hour sessions weekly for 1 year)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no intervention, monitored monthly)
Number of subjects: 97
Study: 26768732

Group type: EXPERIMENTAL
Intervention: US commercial cetuximab (Arm A)
Number of subjects: 148

Group type: COMPARATOR
Intervention: BI-manufactured cetuximab (Arm B)
Number of subjects: 148
Study: 24511914

Group type: EXPERIMENTAL
Intervention: eHealth programme providing personalised pre‐ and postoperative instructions and tools for recovery
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control website access
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: eHealth programme
Number of subjects: 215
Study: 22257997

Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no ethyl chloride spray)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Before skin preparation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: After skin preparation but before application of ethyl chloride
Number of subjects: 15
Study: 21130322

Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split ramus osteotomy (SSRO)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bilateral intraoral vertical ramus osteotomy (IVRO)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (normal occlusion)
Number of subjects: 46
Study: 17651076

Group type: EXPERIMENTAL
Intervention: 1.5 g/day soyoligosaccharide intake (LSO)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 3 g/day soyoligosaccharide intake (HSO)
Number of subjects: 16
Study: 16324022

Group type: EXPERIMENTAL
Intervention: Propofol administered at a rate of 20 mg.30 s(‐1) (i.e. 40 mg.min(‐1)) until BIS value reached 35‐45; Group CP required lower dosage of propofol for induction (P = 0.03).
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (normal children); received propofol at the same rate as Group CP.
Number of subjects: 40
Study: 11519066

Group type: EXPERIMENTAL
Intervention: IL-2 at 9 million IU/day subcutaneously for 1 day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IL-2 at 9 million IU/day subcutaneously for 2 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IL-2 at 9 million IU/day subcutaneously for 3 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Historical control group (22 patients)
Number of subjects: 12
Study: 9435364

Group type: EXPERIMENTAL
Intervention: 0.9% saline solution at a rate of 1000 ml/h
Number of subjects: 27

Group type: COMPARATOR
Intervention: 0.9% saline solution at a rate of 500 ml/h
Number of subjects: 27
Study: 8387966

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg twice daily for the first day, followed by 500 mg once daily for four days)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 14 days)
Number of subjects: 107
Study: 3814200

Group type: EXPERIMENTAL
Intervention: Cyclosporine (10 mg/kg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Azathioprine (2.5‐3 mg/kg/day)
Number of subjects: 24
Study: 2752753

Group type: EXPERIMENTAL
Intervention: Vaginal ring releasing 30 ug/24 hours of 3kDOG (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vaginal ring releasing 15 ug/24 hours of 3kDOG (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cycle
Number of subjects: 20
Study: 31656130

Group type: EXPERIMENTAL
Intervention: Sucralose (8 × 5 g packets/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Steviol glycosides (4 × 1 g packets/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sucrose (8 × 5 g packets/day)
Number of subjects: 38
Study: 28746153

Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Intravenous Patient-Controlled Analgesia (IV-PCA)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 140

Group type: COMPARATOR
Intervention: IV-PCA
Number of subjects: 140
Study: 25251249

Group type: EXPERIMENTAL
Intervention: Virtual reality-based rehabilitation combined with conventional occupational therapy (30 mins/session for 9 sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional occupational therapy (30 mins/session for 15 sessions)
Number of subjects: 40
Study: 23732948

Group type: EXPERIMENTAL
Intervention: Random-sequence condition
Number of subjects: 19

Group type: COMPARATOR
Intervention: Constant-sequence condition
Number of subjects: 19

Group type: COMPARATOR
Intervention: No-sequence condition
Number of subjects: 19
Study: 21282693

Group type: EXPERIMENTAL
Intervention: Routine sterile gloving
Number of subjects: 64

Group type: COMPARATOR
Intervention: Optional sterile gloving
Number of subjects: 64
Study: 19228530

Group type: EXPERIMENTAL
Intervention: E75 peptide vaccine plus granulocyte-macrophage colony-stimulating factor
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (HLA-A2(-) patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: E75 peptide vaccine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: E75 peptide vaccine (excluding 3 patients with PSA recurrences during vaccine series)
Number of subjects: 40
Study: 16564822

Group type: EXPERIMENTAL
Intervention: Higher humidity range (35% to 45%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower humidity range (25% to 35%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of evaporative rates between higher and lower humidity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decrease of 10% RH
Number of subjects: 0
Study: 15232762

Group type: EXPERIMENTAL
Intervention: Elective preterm delivery with management plan including high-resolution ultrasound, weekly re-evaluation, corticosteroids, and delivery if bowel compromise present > 30 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (16 consecutive patients treated prior to management plan)
Number of subjects: 16
Study: 11770188

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Continuous combined HRT
Number of subjects: 48
Study: 9433369

Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8491949

Group type: EXPERIMENTAL
Intervention: Active treatment (local nasal immunotherapy with macronized powder extract)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24
Study: 3434850

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg) tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30452918

Group type: EXPERIMENTAL
Intervention: Endoscopic approach (transluminal drainage with or without necrosectomy, n=34)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Minimally invasive surgery (laparoscopic or video‐assisted retroperitoneal debridement, n=32)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 66

Group type: COMPARATOR
Intervention: Minimally invasive surgery
Number of subjects: 66
Study: 27863331

Group type: EXPERIMENTAL
Intervention: Inpatient enhanced cognitive behavioural therapy for eating disorders (CBT-E)
Number of subjects: 66
Study: 26540083

Group type: EXPERIMENTAL
Intervention: Dalfampridine extended release (D-ER) 10 mg twice daily
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 23410564

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 5145
Study: 21194006

Group type: COMPARATOR
Intervention: Laser treatment to avascular retina (Group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laser treatment to avascular retina and ridge (Group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laser treatment to ridge (Group B)
Number of subjects: 50
Study: 19922017

Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone daily
Number of subjects: 166

Group type: COMPARATOR
Intervention: No prednisolone
Number of subjects: 166
Study: 16863568

Group type: EXPERIMENTAL
Intervention: Enhanced magnification endoscopy (EME) directed biopsies targeting mucosal patterns type III or IV.
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard endoscopy with random biopsies.
Number of subjects: 137
Study: 15242468

Group type: EXPERIMENTAL
Intervention: Mailed video
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Mailed pamphlet
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Usual care/control
Number of subjects: 1152
Study: 11283195

Group type: EXPERIMENTAL
Intervention: Fall risk education, home-based exercise programming, nutrition counseling, and environmental hazards education
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 37
Study: 9416943

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 0
Study: 8496536

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3680538

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (20 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Less vigorous activities (control group)
Number of subjects: 54
Study: 31629767

Group type: EXPERIMENTAL
Intervention: Healthy food images
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hyperpalatable food images
Number of subjects: 18

Group type: COMPARATOR
Intervention: Food addiction status
Number of subjects: 18
Study: 29378982

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study: 25109606

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg daily + intensive lifestyle modification (LSM)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Intensive lifestyle modification (LSM) only
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg daily
Number of subjects: 187
Study: 22669010

Group type: EXPERIMENTAL
Intervention: Tobacco control intervention including health educator visits, discussions led by lead teachers, cessation assistance, posters, and educational materials; implemented over the entire academic year.
Number of subjects: 0
Study: 21715141

Group type: EXPERIMENTAL
Intervention: Intensive bimanual training (Hand‐Arm Bimanual Intensive Therapy: HABIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Constraint‐Induced Movement Therapy, CIMT)
Number of subjects: 20
Study: 18699750

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LS)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Open surgery (OS)
Number of subjects: 233
Study: 16242826

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 27

Group type: COMPARATOR
Intervention: sham TMS
Number of subjects: 27
Study: 14633815

Group type: EXPERIMENTAL
Intervention: Resectional arthroplasty
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard nonsurgical care
Number of subjects: 41
Study: 10749820

Group type: EXPERIMENTAL
Intervention: Carbohydrate loading (9 g CHO/kg body mass/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo-controlled moderate-CHO diet (6 g CHO/kg body mass/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Carbohydrate loading
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo-controlled moderate-CHO diet
Number of subjects: 7
Study: 9051168

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (3 sessions, one weekly for 3 weeks, stimulating Bladder 10 and Gall Bladder 20 points)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (17 patients treated with drugs - FANS and myorelaxing - and physiotherapy)
Number of subjects: 15
Study: 1627436

Group type: EXPERIMENTAL
Intervention: Single cycle of combination chemotherapy (intravenous cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 1275

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Single cycle of combination chemotherapy
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Single cycle of combination chemotherapy (in postmenopausal women with ER-negative tumors)
Number of subjects: 1275

Group type: COMPARATOR
Intervention: No adjuvant treatment (in postmenopausal women with ER-negative tumors)
Number of subjects: 1275
Study: 6392047

Group type: EXPERIMENTAL
Intervention: Nicergoline (Sermion) treatment for one year
Number of subjects: 1366

Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 1366
Study: 30782199

Group type: EXPERIMENTAL
Intervention: CC + SI (sustained inflation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3:1 C:V ratio (compression-to-ventilation ratio)
Number of subjects: 0
Study: 28624862

Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue (AFG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nylon suturing (NS)
Number of subjects: 120
Study: 24990421

Group type: EXPERIMENTAL
Intervention: Exercise (EX; 8-week intervention)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual-care control (CON)
Number of subjects: 25
Study: 23622590

Group type: EXPERIMENTAL
Intervention: ATG tailored according to CD3+ cell count
Number of subjects: 21

Group type: COMPARATOR
Intervention: ATG according to clinical and total lymphocyte count
Number of subjects: 21
Study: 21115860

Group type: EXPERIMENTAL
Intervention: Docetaxel plus trastuzumab (TH)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Docetaxel plus carboplatin and trastuzumab (TCH)
Number of subjects: 263
Study: 19561519

Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine (continue group)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate/emtricitabine (switch group)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 234
Study: 17805132

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Corticotomy‐assisted orthodontic treatment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Anterior segmental osteotomy
Number of subjects: 65
Study: 15105223

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg preincisional and 0.2 mg/kg intraoperative S(+)‐ketamine repeated at 20‐min intervals
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 11378011

Group type: EXPERIMENTAL
Intervention: Talinolol (titrated up to 100 mg/day starting with 12.5 mg daily)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Talinolol (titrated up to 150 mg/day starting with 12.5 mg daily)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Talinolol
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 9839638

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observation of individual tumour response to primary medical treatment
Number of subjects: 0
Study: 9110909

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg a day)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (2000 IU a day)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Combination therapy (selegiline and alpha-tocopherol)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study: 1911319

Group type: EXPERIMENTAL
Intervention: Oral terbinafine, 250 mg, once daily for 2 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo, once daily for 2 weeks
Number of subjects: 53
Study: 6286087

Group type: EXPERIMENTAL
Intervention: 4000 rad split course (2000 rad in five fractions in one week, two weeks rest and additional 2000 rad in five fractions in one week)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 4000 rad continuous course
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 5000 rad continuous course
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 6000 rad continuous course
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 4000 rad (split or continuous course)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 5000 to 6000 rad
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 4000 rad (for tumors 3 cm or less)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 5000 to 6000 rad (for tumors 3 cm or less)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 4000 rad (for lesions 4 to 6 cm)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 5000 rad (for lesions 4 to 6 cm)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 6000 rad (for lesions 4 to 6 cm)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 4000 rad
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 5000 rad
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 6000 rad
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Protocol compliance (irradiated at the primary site according to protocol instruction)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Major protocol variations in nodal irradiation
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Variations in ipsilateral and contralateral nodal irradiation
Number of subjects: 378
Study: 31577867

Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole (1-3 mg/d)
Number of subjects: 3850

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3850

Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole (0.5-3 mg/d)
Number of subjects: 3850

Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole
Number of subjects: 3850
Study: 30280635

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (200 mg of pembrolizumab, carboplatin, and either paclitaxel or nab-paclitaxel)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Saline placebo plus chemotherapy (saline placebo, carboplatin, and either paclitaxel or nab-paclitaxel)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 559

Group type: COMPARATOR
Intervention: Saline placebo plus chemotherapy
Number of subjects: 559
Study: 26536083

Group type: EXPERIMENTAL
Intervention: High cut-off (HCO) membrane
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-flux membrane
Number of subjects: 24
Study: 25189359

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus‐eluting stents
Number of subjects: 2119

Group type: COMPARATOR
Intervention: Durable polymer everolimus‐eluting stents
Number of subjects: 2119

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus‐eluting stents (in ST-segment elevation myocardial infarction subgroup)
Number of subjects: 2119

Group type: COMPARATOR
Intervention: Durable polymer everolimus‐eluting stents (in ST-segment elevation myocardial infarction subgroup)
Number of subjects: 2119
Study: 22519478

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 200
Study: 20142339

Group type: EXPERIMENTAL
Intervention: Strepsils
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 19223678

Group type: EXPERIMENTAL
Intervention: Sprint training group (STG)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coordination training group (CTG)
Number of subjects: 16
Study: 16159843

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 167

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 167
Study: 12382295

Group type: EXPERIMENTAL
Intervention: Knee bandage applied
Number of subjects: 20

Group type: COMPARATOR
Intervention: No bandage applied (Control)
Number of subjects: 20
Study: 9763330

Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol hydrochloride
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate
Number of subjects: 149